Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

NCT05021328 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Toripalimab
DRUG: Anlotinib
DRUG: SBRT 7Gy✖️5 QD

Sponsor

Hubei Cancer Hospital